Acadia Pharmaceuticals Inc (ACAD)

Apr 28, 2025

Acadia Pharmaceuticals (ACAD) Sees Price Target Cut by UBS | ACA - GuruFocus

Apr 28, 2025

Apr 28, 2025

UBS Adjusts ACADIA Pharmaceuticals Price Target to $22 From $25, Maintains Buy Rating - marketscreener.com

Apr 28, 2025

Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025

Apr 23, 2025

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025 - BioSpace

Apr 23, 2025

Apr 22, 2025

Parkinson’s Disease Therapeutic Domain Projected to See Transformational Growth Across the 7MM During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.

Apr 22, 2025

Apr 21, 2025

Acadia Pharmaceuticals (ACAD) Price Target Lowered by BofA Before Q1 Earnings | ACAD Stock News - GuruFocus

Apr 21, 2025

Apr 21, 2025

Acadia Pharmaceuticals price target lowered to $18 from $19 at BofA - MSN

Apr 21, 2025

Apr 17, 2025

BofA Adjusts Price Target on ACADIA Pharmaceuticals to $18 From $19, Keeps Neutral Rating - marketscreener.com

Apr 17, 2025

Apr 15, 2025

Schizophrenia Market to Reach New Heights in Growth by 2034, - openPR.com

Apr 15, 2025

Apr 13, 2025

Declining Stock and Solid Fundamentals: Is The Market Wrong About ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)? - Yahoo Finance

Apr 13, 2025

Apr 12, 2025

Lobbying Update: $20,000 of ACADIA PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative

Apr 12, 2025

Apr 11, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Li - GuruFocus

Apr 11, 2025

Apr 11, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ACAD Stock News - GuruFocus

Apr 11, 2025

Apr 11, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Apr 11, 2025

Apr 10, 2025

Acadia (ACAD) Stock Jumps 6.1%: Will It Continue to Soar? - Yahoo Finance

Apr 10, 2025

Apr 09, 2025

Acadia Pharmaceuticals principal accounting officer sells $15,234 in stock By Investing.com - Investing.com South Africa

Apr 09, 2025

Apr 09, 2025

Acadia Pharmaceuticals principal accounting officer sells $15,234 in stock - Investing.com Australia

Apr 09, 2025

Apr 08, 2025

Acadia Pharmaceuticals CFO sells $40,132 in stock By Investing.com - Investing.com India

Apr 08, 2025

Apr 08, 2025

Acadia Pharmaceuticals CFO sells $40,132 in stock - Investing.com

Apr 08, 2025

Apr 08, 2025

ACADIA Pharmaceuticals Executives Sell Shares to Cover Taxes - TradingView

Apr 08, 2025

Apr 08, 2025

Is Weakness In ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? - simplywall.st

Apr 08, 2025

Apr 08, 2025

ACADIA stock touches 52-week low at $14.14 amid market challenges - Investing.com

Apr 08, 2025

Apr 04, 2025

RBC Capital Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD) - The Globe and Mail

Apr 04, 2025

Mar 31, 2025

DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm - Business Wire

Mar 31, 2025

Mar 31, 2025

ACADIA Pharmaceuticals Earns Relative Strength Rating Upgrade - Investor's Business Daily

Mar 31, 2025

Mar 28, 2025

Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report? - Yahoo Finance

Mar 28, 2025

Mar 27, 2025

Soleno breaks through with FDA nod for Prader-Willi syndrome treatment Vykat XR - Fierce Pharma

Mar 27, 2025

Mar 27, 2025

Soleno jumps as analysts say US nod for rare disease drug transforms treatment options - Marketscreener.com

Mar 27, 2025

Mar 27, 2025

SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug - Yahoo Finance

Mar 27, 2025

Mar 27, 2025

Acadia Pharmaceuticals principal accounting officer sells $18k in stock By Investing.com - Investing.com Canada

Mar 27, 2025

Mar 26, 2025

Acadia Pharmaceuticals CFO sells $54,065 in stock By Investing.com - Investing.com Canada

Mar 26, 2025

Mar 26, 2025

Acadia Pharmaceuticals CFO sells $54,065 in stock - Investing.com India

Mar 26, 2025

Mar 26, 2025

Acadia Pharmaceuticals principal accounting officer sells $18k in stock - Investing.com

Mar 26, 2025

Mar 25, 2025

Is ACADIA Pharmaceuticals Inc. (ACAD) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey

Mar 25, 2025

Mar 25, 2025

Psychosis in Parkinson's and Alzheimer's Disease Market: - openPR

Mar 25, 2025

Mar 24, 2025

Parkinson's Disease Psychosis Treatment Market Size in 7MM - openPR

Mar 24, 2025

Mar 20, 2025

Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer’s Disease Psychosis - Business Wire

Mar 20, 2025

Mar 18, 2025

Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome - Business Wire

Mar 18, 2025

Mar 17, 2025

Is ACADIA Pharmaceuticals Inc. (ACAD) the Best Nasdaq Stock Under $20 to Buy Now? - Insider Monkey

Mar 17, 2025

Mar 17, 2025

ACADIA Pharmaceuticals Earns RS Rating Upgrade - Investor's Business Daily

Mar 17, 2025

Mar 16, 2025

Former San Diego Pharma VP pleads guilty to securities fraud for insider trading - MSN

Mar 16, 2025

Mar 16, 2025

Ryan Reynolds Announces More to Parkinson’s® Campaign - Business Wire

Mar 16, 2025

Mar 14, 2025

Acadia Pharmaceuticals issues new employee stock awards By Investing.com - Investing.com Australia

Mar 14, 2025

Mar 14, 2025

Acadia Pharmaceuticals issues new employee stock awards - Investing.com India

Mar 14, 2025